1 Semaglutide has similar adverse events but also includes headache, vitreous hemorrhage in patients with diabetic retinopathy, anxiety, dizziness, and erythema at the injection site
Confirm prior authorization requirements and formulary coverage before starting treatment
Researchers looked at data from 46,000 patients who had received a GLP-1 drug for at least six months, compared with 92,000 patients who had not taken these drugs
Every four weeks, your Wegovy dose is increased until you reach the maintenance dose
UnitedHealthcare has a two-level appeal process: Level 1 appeal (internal): Submit within 180 days of denial Include provider letter explaining medical necessity Include supporting clinical documentation (labs, medication trial records, weight logs) Decision within 30 days for standard appeals, 72 hours for urgent appeals Approval rate on Level 1 appeals: 22% Level 2 appeal (external review): Available if Level 1 denied Reviewed by independent third party, not UnitedHealthcare Must file within 60 days of Level 1 denial Decision is binding on UnitedHealthcare Approval rate on Level 2 appeals: 38% The appeal success rate is higher for diabetes indication (45% combined Level 1 + Level 2) than weight-loss indication (28% combined)
As PlexusDx patients lose weightoften 1015% within 6 monthsblood vessel pressure naturally decreases, potentially requiring dose reductions in blood pressure medications